Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis Publisher Pubmed



Khorrami M1 ; Saneipour M2 ; Moridnia A2 ; Shaygannejad V3 ; Sadeghi E4 ; Kassani A5 ; Sarmadi A1 ; Mirmosayyeb O3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Genetics and Molecular Biology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
  3. 3. Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Sciences Isfahan Iran, Isfahan, Iran
  5. 5. Department of Community Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran

Source: International Journal of Neuroscience Published:2024


Abstract

Objective: Multiple sclerosis (MS) is a multifactorial inflammatory and autoimmune condition that lead to chronic neurodegeneration and central nervous system (CNS) demyelination that mainly affects young adults. The incidence and prevalence rate of MS considerably vary in ethnicities and geographic regions and affecting women more than men. Interferon-β (IFN-β) is the first-line disease management for MS, while the majority of affected members does not respond to the IFN-β. Numerous recent studies shown a significant relationship between genetic variations and responsiveness to the IFN-β. Therefore, determining the genetic differences in the drug response could help determine precise treatment strategies. Methods: The genotyping of the rs7298096 polymorphism (SNP) and NINJ2 gene expression were assessed in 99 responders and 106 non-responder patients with IFN-β treated RRMS. Results: The distribution of rs7298096 SNP was significantly different in the responders and non-responder patients and the NINJ2 gene expression considerably increased in the non-responder patients compare to the responders. The NINJ2 gene expression level in the AA genotype of the non-responder group was higher than to the other genotypes of both groups. Conclusion: Our results showed that the NINJ2 gene expression level and rs7298096 genotype possibly affect the response to the IFN-β in patients with RRMS. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. An Interdependence Between Gapvd1 Gene Polymorphism, Expression Level and Response to Interferon Beta in Patients With Multiple Sclerosis, Journal of Neuroimmunology (2021)
2. High-Resolution Melting Curve Analysis of Polymorphisms Within Cd58, Cd226, Hla-G Genes and Association With Multiple Sclerosis Susceptibility in a Subset of Iranian Population: A Case–Control Study, Acta Neurologica Belgica (2020)
3. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
4. Risk Factor Effect of Rs1044165 and Rs3745453 As Neighboring Variants of Mir-223, Mir-24, Mir-23A and Mir-27A on the Onset of Ms Disease in Isfahan/Iran, Gene Reports (2018)
5. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
6. Interleukin 18 Polymorphisms and Its Serum Level in Patients With Multiple Sclerosis, Annals of Indian Academy of Neurology (2019)
7. Number and Volume of Demyelinative Plaques Can Predict the Response to Treatment in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2011)
8. Association of Interleukin-1 Gene Cluster Polymorphisms and Haplotypes With Multiple Sclerosis in an Iranian Population, Journal of Neuroimmunology (2015)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (85)
Vahid Shaygannejad (75)
Other Related Docs
9. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
10. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
11. Association of Aire Polymorphism and the Susceptibility to Multiple Sclerosis in Iranian Population, Avicenna Journal of Medical Biotechnology (2018)
12. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
13. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
14. Evaluation of the Frequency of Osteopontin Gene Polymorphism (Rs28357094 T>G) and Its Receptor Gene (Itga4- Rs1449263 A>G) in Multiple Sclerosis Patients in Comparison to Healthy Controls in Isfahan, Iran, Population, Journal of Isfahan Medical School (2016)
15. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
16. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
17. The Frequency of Varicella-Zoster Virus Infection in Patients With Multiple Sclerosis Receiving Fingolimod, Journal of Neuroimmunology (2019)
18. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
19. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
20. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
21. Expression and Clinical Significance of Il7r, Nfatc2, and Rnf213 in Familial and Sporadic Multiple Sclerosis, Scientific Reports (2021)
22. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
23. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
24. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
25. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
26. Targeted Mutations in Val101 and Arg27 Interferon Beta Protein Increase Its Transcriptional and Translational Activities, Cytokine (2016)
27. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, Cell Journal (2017)
28. Association of Cd24v/V Genotype With Susceptibility and Progression of Multiple Sclerosis in Iranian Population, Iranian Journal of Biotechnology (2008)
29. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
30. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
31. Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2018)
32. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
33. Efficacy of Adding Vitamin D Supplementation to Interferon Β-1 in Multiple Sclerosis, Journal of Isfahan Medical School (2016)
34. Genetic Variation in Intergenic and Exonic Mirna Sequence and Risk of Multiple Sclerosis in the Isfahan Patients, Iranian Journal of Allergy, Asthma and Immunology (2018)
35. Patient Preferences for Interferon-Beta in Iran: A Discrete Choice Experiment, PLoS ONE (2018)
36. Cd24 Gene Allele Variation Is Not Associated With Oligoclonal Igg Bands and Igg Index of Multiple Sclerosis Patients, NeuroImmunoModulation (2012)
37. The Effect of Ifn-Β Treatment on Plasma Levels of Bdnf and Il-6 in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2021)
38. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
39. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
40. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
41. Comparing the Frequency of Tim-3 Polymorphism in Multiple Sclerosis Patients With Healthy Controls, Journal of Isfahan Medical School (2015)
42. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
43. Investigation of Erg Gene Expression in Iranian Patients With Multiple Sclerosis, Immunological Investigations (2018)
44. The Role of Non-Hla Single Nucleotide Polymorphisms in Multiple Sclerosis Susceptibility, Journal of Neuroimmunology (2010)
45. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
46. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
47. Promising Effect of Rapamycin on Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2018)
48. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
49. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
50. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)